Today's Date: March 23, 2023
TAL ALERT: Bragar Eagel & Squire, P.C. is Investigating TAL Education Group on Behalf of TAL Stockholders and Encourages Inv   •   Fire Victim Trust Settles Vegetation Management Claims For $171m   •   PepsiCo Juntos Crecemos and Celebrity Chef Lorena Garcia Team Up to Support Jefa-Owned Businesses on National Jefa Day   •   L.A. Care and Blue Shield of California Promise Health Plans Open New Community Resource Center in Norwalk   •   FOOD AS MEDICINE: Spartan Medical Answers the Call to Help Veterans Eat Healthier Aligned with the Department of Veterans Affair   •   The Law Offices of Frank R. Cruz Announces Investigation of Block, Inc. (SQ) on Behalf of Investors   •   Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets   •   CRTC to improve access to Internet and mobile services across Canada   •   Swisslog Healthcare Promotes Eric Waski to Senior Vice President – Technology Center   •   Inovia Vein Leads Community Outreach for DVT Awareness Month   •   RedDrop Announces Bold Stance to Support Early Menstruating Girls in Florida with $15M Donation In Services   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in DISH Network Corporation with Losses of $100,000 to Contac   •   Canadian securities regulators publish detailed data for eighth annual review of representation of women on boards in Canada   •   /C O R R E C T I O N -- Autism Speaks/   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Block, Inc. (SQ) on Behalf of Investors   •   Xavier Cole named 18th president of Loyola University New Orleans   •   Agilent Presents 2023 Darlene Solomon Award to Victor Chang Cardiac Research Institute Scientist, Kathryn Wolhuter   •   Stratus Financial Will Join Sun N Fun Aerospace Expo 2023   •   NEI sets human rights, inequality, net zero, nature as focus themes for corporate engagement   •   Gaming Arts will showcase an impressive lineup of new titles displaying creativity and innovation at IGA 2023
Bookmark and Share

Curio Bioscience Launches Industry’s First Unbiased, High-Resolution, Spatial Transcriptomics Solution

PALO ALTO, Calif. , February 08 /Businesswire/ - Curio Bioscience today announced it has commenced commercial operations with the launch of Curio Seeker, the world’s first high-resolution, whole-transcriptome spatial mapping kit. Leveraging the Slide-seq technique that its academic co-founders created at the Broad Institute of MIT and Harvard, Curio Seeker enables any laboratory to generate whole-transcriptome spatial data from tissue samples in an easy-to-use workflow.

This press release features multimedia. View the full release here:

“We have known for years that the spatial mapping of tissue has the potential to accelerate novel discoveries and advance our understanding of human biology,” said Steve Fodor, Ph.D., Co-founder and CEO of Curio Bioscience. “Curio Seeker is an innovative, new tool that enables life science researchers to access high-resolution transcriptomics information in their organism of choice. We believe that Curio Seeker will take discovery beyond what is possible with current single-cell sequencing approaches and establish a new industry standard for spatial transcriptomics.”

Curio’s academic co-founders are Evan Macosko, M.D., Ph.D., Associate Professor of Psychiatry at Massachusetts General Hospital and Institute Member at the Broad Institute, Fei Chen, Ph.D., Assistant Professor in Harvard University’s Department of Stem Cell and Regenerative Biology and Core Institute Member at the Broad, and Samuel Rodriques, Ph.D., Group Leader at The Francis Crick Institute.

“Until now, researchers considering spatial genomics tools have had to choose between unbiased methods that provide high transcriptomic coverage at the cost of resolution, or targeted methods that provide high resolution data across only a subset of targets,” said Macosko. “The novel and validated technique on which Curio Seeker is based allows researchers to use existing sequencing instrumentation to generate unbiased, high-resolution spatial transcriptomics data across many tissue types and species, unlocking new avenues for basic scientific discovery.”

Without the need for traditional microscopy-based approaches, Curio Seeker provides the ability to generate tissue images by molecularly profiling cells in their spatial location using standard next generation sequencers. Researchers can capture and map where RNA molecules are in the tissue to better understand the relationship between cells and their native environment. Curio Seeker provides a baseline for understanding developmental biology, assessing the immunological response to cancer, and discovering molecular signatures that predict disease progression or treatment response among other studies.

“The ability to do whole-transcriptome, spatial mapping of tissue at industry-leading resolution with a simple, plug-and-play workflow is revolutionary in the biological research field,” said Christina Fan, Ph.D., Co-founder and CTO at Curio. “No other technique on the market today provides the depth and breadth of information on cellular neighborhoods that Curio Seeker can for biological research.”

Curio Seeker is the first in a suite of products that the company is developing that enable high-resolution discovery using existing sequencing instrumentation. With industry-leading 1-2 cell average resolution that minimizes gaps, the kit enables scientists to get the most transcriptomic data from their samples. The solution is compatible with all Illumina sequencers, allowing for plug-and-play use of the kit in existing sequencing workflows with no additional equipment needed.

“Curio Seeker has furthered our understanding of the microenvironment and spatial relationships between cells in various tissues of interest. We have already applied this new tool to a wide range of organisms to learn how diverse cell populations interact, simplifying complex challenges. Furthermore, the Curio Seeker kit was both easy to implement and affordable,” said Dr. Angela Pisco, Assistant Director Bioinformatics at Chan Zuckerberg Biohub.

About Curio Bioscience

Curio Bioscience is a company advancing a new generation of high-precision tools for the life sciences industry. The company has developed innovative spatial biology capabilities to map the whole transcriptome at high resolution using existing sequencing workflows and instrumentation. Curio’s founding team has a strong track record of bringing genomic solutions to market. Based in Palo Alto, California, Curio Bioscience is a privately held company. For more information, go to

STORY TAGS: Photo/Multimedia, Product/Service, United States, North America, Health, Medical Devices, Health Technology, Genetics, Research, Science, Biotechnology, California,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News